Spinal-Fluid injection targets Hard-to-Reach lung cancer spread
NCT ID NCT07702305
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This phase 1 trial tests an experimental drug, sacituzumab tirumotecan (SKB264), given directly into the spinal fluid of people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). The study enrolls adults whose cancer has stopped responding to standard targeted therapy. The goal is to find a safe dose and see if the drug can shrink the cancer in the central nervous system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibody-drug conjugate called sacituzumab tirumotecan (SKB264), given as an injection into the spinal fluid
- What this could lead to
- If this works, it could offer a new treatment option for people with a hard-to-treat form of lung cancer that has spread to the lining of the brain and spinal cord.
- What could go wrong
- This is a very early, small trial (8-15 people) focused on finding the right dose and checking safety. It may not lead to a proven treatment, and there are risks like nerve damage and bone marrow suppression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER WITH LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.